张成阳今天将为大家解读公司2024年的经营成果核心业务的进展及未来发展战略也希望通过本次交流能帮助各位更全面的更清晰的了解公司的价值首先是公司2024年业绩概括公司2024年业绩稳重提升核心业务真性凸显2024年面对不达多变的外部环境公司聚焦了 医药健康主业持续优化业务结构全年实现有营业收入39.83亿元推出善务者股东的净利润为2.44亿元尽管受到地产业务博弈的影响整体收入露营超时重新录制请按1露营超时重新录制请按1露营超时 重新录制请按1录音超时重新录制请按1录音超时重新录制请按1录音超时重新录制请按1录音超时重新录制我继续按玻璃贴 去年地产一年初我们就进行了全部的剥离所以如果剔除地产业务的影响的话2024年整体业务和2023年基本制品扣费利润同比增长了54.54%充分体现了公司主要业务的一个强劲人性和营利能力有所提升首先呢财务亮点华融平板块2024年华融平业务收入是24.75亿元同比增长了2.46% 毛利率62.57同比增长0.25个百分比研发投入全年公司研发费用1.99亿元同比增长20.05%新增了授权专利64项技术的壁垒持续得到巩固现金流健康金融活动现金流金额2.29亿元投资活动现金流金额29.93亿 ...

证券代码：600223 证券简称：福瑞达 编号：临2025-012 登录新浪财经APP 搜索【信披】查看更多考评等级 重要内容提示： ● 问题征集方式：投资者可于2025年4月8日（星期二）至4月14日（星期一）16:00前将需要了解的情况 和相关问题通过电子邮件的形式发送至公司投资者关系邮箱：lsfrd600223@163.com。公司将在业绩说 明会上对投资者普遍关注的问题进行回答。 鲁商福瑞达医药股份有限公司（以下简称"公司"）已于2025年3月22日披露公司2024年年度报告，为了 便于广大投资者更全面深入地了解公司2024年业绩和经营情况，公司拟于2025年4月15日（星期二） 15:00-17:00举行2024年度业绩说明会，就投资者普遍关心的问题进行交流。 一、业绩说明会类型 本次投资者说明会以视频结合网络互动的形式召开，公司将针对2024年业绩和经营情况与投资者进行交 流，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、业绩说明会召开的时间、地点 三、参加人员 鲁商福瑞达医药股份有限公司 关于召开2024年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 ...

证券代码：600223 证券简称：福瑞达 编号：临 2025-012 鲁商福瑞达医药股份有限公司 关于召开 2024 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 问题征集方式：投资者可于 2025 年 4 月 8 日（星期二）至 4 月 14 日 （星期一）16:00 前将需要了解的情况和相关问题通过电子邮件的形式发送至公 司投资者关系邮箱：lsfrd600223@163.com。公司将在业绩说明会上对投资者普 遍关注的问题进行回答。 鲁商福瑞达医药股份有限公司（以下简称"公司"）已于 2025 年 3 月 22 日 披露公司 2024 年年度报告，为了便于广大投资者更全面深入地了解公司 2024 年业绩和经营情况，公司拟于 2025 年 4 月 15 日（星期二）15:00-17:00 举行 2024 年度业绩说明会，就投资者普遍关心的问题进行交流。 一、业绩说明会类型 本次投资者说明会以视频结合网络互动的形式召开，公司将针对 2024 年业 绩和经营情况与投资者进行交流，在信息 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 15% compared to the market in the next six months [4]. Core Insights - The company's core business remains stable, with a notable improvement in gross margin. In 2024, the company achieved revenue of 3.983 billion yuan, a year-on-year decrease of 13.02%, primarily due to the impact of the real estate business divestiture. Excluding real estate, core business revenue remained flat. The net profit attributable to shareholders was 244 million yuan, down 19.73% year-on-year, while the net profit excluding non-recurring items was 215 million yuan, up 54.54% year-on-year [1][2]. Summary by Sections Financial Performance - In Q4, the company recorded revenue of 1.180 billion yuan, a slight decline of 0.33% year-on-year, with a net profit of 72 million yuan, an increase of 10.72% year-on-year [1]. - The gross margin improved by 6.19 percentage points to 52.68% in 2024, mainly due to the divestiture of low-margin real estate business and optimization of the cosmetics and raw materials business structure. The net profit margin decreased by 0.56 percentage points to 7.44% [2]. Business Segments - The cosmetics segment generated revenue of 2.475 billion yuan in 2024, a year-on-year increase of 2.46%, with a gross margin of 62.57%. The "Yilian" brand achieved revenue of 963 million yuan, up 12.36% year-on-year, while "Aier Doctor" reported revenue of 1.301 billion yuan, down 3.48% year-on-year [3]. - The pharmaceutical segment's revenue was 512 million yuan, a decrease of 1.41% year-on-year, with a gross margin of 52.32%. The company is expanding its distribution channels and launching new functional food products [3]. Profit Forecast - The company forecasts revenues of 4.389 billion yuan in 2025, 4.710 billion yuan in 2026, and 5.056 billion yuan in 2027, with corresponding growth rates of 10.20%, 7.32%, and 7.34% respectively. The net profit attributable to shareholders is expected to be 283 million yuan in 2025, 317 million yuan in 2026, and 360 million yuan in 2027 [4][10].

转自：大众报业·齐鲁壹点 活动当日，善颜品牌联合老年大学举办主题沙龙，特邀资深培训师李维娜与品牌培训顾问田霞联袂主讲。李维娜从胶原蛋白流失、弹性 纤维断裂等机理切入，结合影像化呈现解析衰老科学；田霞则通过现场演示家居提拉手法与善颜明星产品试用，让参与者直观感受"分肤 定制"的精准抗衰科技。活动不仅传递了"抗衰不分年龄"的理念，更以"优雅老去亦能焕发新生"的品牌温度，引发共鸣。 此次合作是福瑞达集团与新华书店集团"文化+科技"战略的起点。未来，双方计划以山东书城为样板，拓展至省内多地书店场景，并探索 AI肤质诊断等数字化交互，打造季节限定主题快闪体验。此外，双方还将联合推出系列文化沙龙、美妆研学工坊，深化"智美山东"品牌 内涵，为山东经济高质量发展注入新动能。 从一本好书到一瓶科技护肤臻品，从文化地标到创新消费场景，福瑞达集团与新华书店的跨界实践，不仅重构了美妆与文化的连接方 式，更以国企担当为产业升级提供了鲜活样本。这场关于美的探索，正以书香为笔，科技为墨，绘就齐鲁大地"智美共生"的未来画卷。 福瑞达集团与山东新华书店集团于2024年12月签署战略合作协议，以"文化链接、科技协同"为框架，致力于探索新零售融合 ...

中国国际金融股份有限公司 关于 鲁商福瑞达医药股份有限公司 重大资产出售暨关联交易 之 2024年度持续督导意见暨持续督导总结报告 独立财务顾问 声明与承诺 中国国际金融股份有限公司接受鲁商福瑞达医药股份有限公司委托，担任鲁商福瑞 达医药股份有限公司重大资产出售暨关联交易之独立财务顾问。本独立财务顾问按照证 券行业公认的业务标准、道德规范和诚实信用、勤勉尽责精神，遵循客观、公正的原则， 出具本持续督导意见。 1、本持续督导意见所依据的文件和材料由本次交易各方提供，提供方对所提供文件 及资料的真实性、准确性和完整性负责，并保证该等信息不存在虚假记载、误导性陈述 或者重大遗漏。本独立财务顾问不承担由此引起的任何风险责任。 2、本独立财务顾问已按照规定履行持续督导义务，有充分理由确信所发表的专业意 见与上市公司披露的文件内容不存在实质性差异，确信上市公司信息披露文件真实、准 确、完整。 3、本持续督导意见不构成对上市公司的任何投资建议，投资者根据本持续督导意见 所做出的任何投资决策而产生的相应风险，本独立财务顾问不承担任何责任。 4、本独立财务顾问未委托和授权任何其它机构和个人提供未在本持续督导意见中列 载的信息和 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative return of over 20% within the next six months [6][18]. Core Insights - The company achieved a revenue of 3.983 billion yuan in 2024, a year-on-year decrease of 13.02%, but a 6% growth when excluding the impact of the real estate business. The net profit attributable to the parent company was 244 million yuan, down 19.73% year-on-year, while the non-recurring net profit increased by 54.54% to 215 million yuan [1][5]. - The gross margin for 2024 was 52.68%, up 6.19 percentage points year-on-year, while the sales expense ratio increased significantly to 44.77%, up 3.71 percentage points [2]. - The cosmetics segment showed steady growth, with revenue of 2.475 billion yuan, a year-on-year increase of 2.46%, accounting for 62.76% of total revenue. The gross margin for this segment was 62.57% [3][4]. Financial Performance - In Q4 2024, the company reported revenue of 1.180 billion yuan, a slight decrease of 0.33% year-on-year, with a net profit of 72 million yuan, an increase of 10.72% year-on-year. The non-recurring net profit for Q4 was 64 million yuan, up 104.37% [1][2]. - The company plans to distribute a cash dividend of 0.6 yuan per 10 shares, totaling 60.99 million yuan [1]. - The projected revenues for 2025-2027 are 4.281 billion yuan, 4.672 billion yuan, and 5.060 billion yuan, respectively, with net profits expected to be 291 million yuan, 322 million yuan, and 365 million yuan [5][12]. Brand Strategy and Market Position - The company employs a multi-brand strategy with a focus on the "5+N" brand development model, which has led to rapid growth in its cosmetics segment. Collaborations with cultural IPs have boosted sales significantly [4]. - The company is expanding its product offerings in the health sector, including the launch of new health-oriented products and the establishment of a supply chain service platform [5].

点评： 24 年剔除地产业务影响归母净利润同比增长6%24 年公司实现营业收入39.83 亿元，同比下降 13.02%，实现归母净利润2.44 亿元，同比下降19.73%，实现扣非归母净利润 2.15 亿元，同比增长 54.54%。剔除地产业务影响收入基本持平，归母净利润同比增长6.15%。 盈利能力方面，2024 年公司毛利率为52.68%，同比上升6.19pct，净利率为7.44%，同比下降 0.56pct。费用率方面，24 年公司销售费用率为36.73%，同比提升5.14pct；管理费用率为4.59%，同比下 降0.28pct；研发费用率为 4.19%，同比上升0.84pct。 化妆品板块表现稳健，医药和原料板块调整期略有下滑分业务来看，化妆品板块2024 年实现营业 收入24.75 亿元，同比上升2.46%，毛利率62.57%，同比增加0.44pct。其中，颐莲品牌实现营业收入9.63 亿元，同比上升12.36%，喷雾1.0 销售同比增长13%，喷雾2.0 销售同比增长35%，顺利完成迭代；嘭润 品线实施"亿元面霜"计划，嘭润霜销售同比增长18%。瑷尔博士实现营业收入13.01 亿元，同比下降 3.4 ...

公司报告 | 年报点评报告 福瑞达发布 2024 年年报： 2024 年公司实现营收 39.83 亿元，yoy-13.02%；归母净利润 2.44 亿元， yoy-19.73%，剔除地产业务影响后增速为 6%；扣非归母净利润 2.15 亿元， yoy+54.54%。2024Q4 实现营收 11.80 亿元，yoy-0.33%，归母净利润 0.72 亿元，yoy+10.72%；扣非归母净利润 0.64 亿元，yoy+104.37%。公司预计 按每 10 股派发现金股利 0.6 元（含税），合计派发现金股利 60.99 百万元。 毛利率稳中有升，销售费用率受业务调整影响显著提升： 2024 年毛利率 52.68%，同比+6.19pct；销售费用率 44.77%，同比+3.71pct； 管理费用率 4.59%，同比-0.28pct；研发费用率 4.19%，同比+0.84pcts；净 利率 7.44%，同比-0.56pct。2024Q4 毛利率 54.65%，同比+9.87pct；销售费 用率 37.33%，同比+7.04pcts；管理费用率 5.4%，同比-0.15pct；研发费用 率 5.34%，同比+0.87p ...

Investment Rating - The report maintains a "Buy" rating for the company [4] Core Insights - The company reported a 6% year-on-year growth in net profit attributable to the parent company after excluding the impact of the real estate business, despite a 13.02% decline in total revenue to 3.983 billion yuan [2] - The cosmetics segment showed resilience with a revenue increase of 2.46% to 2.475 billion yuan, while the pharmaceutical and raw materials segments experienced slight declines [3] - The company is focusing on the health sector after divesting its real estate business, leveraging strong R&D capabilities to drive quality growth in its cosmetics business [4] Financial Performance Summary - In 2024, the company achieved total revenue of 3.983 billion yuan, a decrease of 13.02% year-on-year, and a net profit of 244 million yuan, down 19.73% year-on-year [2] - The adjusted net profit, excluding the real estate business, showed a growth of 6.15% [2] - The gross margin for 2024 was 52.68%, an increase of 6.19 percentage points year-on-year, while the net margin was 7.44%, a decrease of 0.56 percentage points [2] - The cosmetics segment's revenue was 2.475 billion yuan, with a gross margin of 62.57% [3] - The company forecasts EPS of 0.29, 0.34, and 0.39 yuan for 2025, 2026, and 2027 respectively, with corresponding PE ratios of 26, 22, and 19 [4]